Biolinerx LTD. (BLRX) — SEC Filings

Q: What are the key financial highlights for Biolinerx LTD.?

Key financial highlights for Biolinerx LTD. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Biolinerx LTD.?

Key executives at Biolinerx LTD. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Biolinerx LTD. stock?

Risk factors for Biolinerx LTD. (BLRX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Biolinerx LTD.?

Forward-looking statements and predictions from Biolinerx LTD. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Biolinerx LTD.. Recent 6-K filing on Mar 26, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Biolinerx LTD. on SEC EDGAR

Overview

Biolinerx LTD. (BLRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Mar 26, 2026: BioLineRx Ltd. filed a 6-K report on March 26, 2026, indicating a routine foreign issuer report. This filing, with accession number 0001178913-26-001738, includes several exhibits and graphics, but does not disclose any specific new financial or operational information. For investors, this particula

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 33 neutral. The dominant filing sentiment for Biolinerx LTD. is neutral.

Filing Type Overview

Biolinerx LTD. (BLRX) has filed 33 6-K, 1 20-F, 1 20-F/A with the SEC between Feb 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (35)

BioLineRx Files Routine 6-K Foreign Issuer Report on March 26, 2026 — 6-K · Mar 26, 2026
BioLineRx Ltd. filed a 6-K report on March 26, 2026, indicating a routine foreign issuer report. This filing, with accession number 0001178913-26-001738, includ
6-K Filing — 6-K · Nov 24, 2025
6-K Filing — 6-K · Nov 17, 2025
BioLineRx Ltd. Forms Joint Venture with Hemispherian AS — 6-K · Sep 29, 2025 Risk: medium
On September 29, 2025, BioLineRx Ltd. entered into a joint venture with Hemispherian AS, a Norwegian corporation, for the development and clinical trials of a d
BioLineRx Ltd. Reports Q2 2025 Financial Results — 6-K · Aug 14, 2025 Risk: medium
BioLineRx Ltd. announced its financial results for the three and six months ended June 30, 2025, on August 14, 2025. The company, incorporated in Israel, is a f
BioLineRx Ltd. Holds Annual Shareholder Meeting — 6-K · Jun 30, 2025 Risk: low
BioLineRx Ltd. announced the results of its Annual General Meeting of Shareholders held on June 29, 2025. The meeting took place at 3:00 p.m. Israel time, and s
BioLineRx Ltd. Files Form 6-K Reporting Press Release — 6-K · May 30, 2025 Risk: low
BioLineRx Ltd. filed a Form 6-K on May 30, 2025, to report a press release issued on the same date. The filing does not contain specific financial figures or op
BioLineRx Ltd. Reports Q1 2025 Financial Results — 6-K · May 27, 2025 Risk: low
BioLineRx Ltd. announced its financial results for the three months ended March 31, 2025, on May 27, 2025. The company also published its unaudited interim cons
BioLineRx Sets Annual Shareholder Meeting for June 29 — 6-K · May 23, 2025 Risk: low
BioLineRx Ltd. announced on May 23, 2025, that its Annual Meeting of Shareholders will take place on June 29, 2025, at 3:00 p.m. Israel time. The meeting will b
BioLineRx Ltd. Files 20-F for FY2024 — 20-F · Mar 31, 2025 Risk: medium
BioLineRx Ltd. filed its 20-F for the fiscal year ending December 31, 2024. The filing details its business operations, financial performance, and risk factors.
BioLineRx Ltd. Files Form 6-K Reporting Press Release — 6-K · Jan 21, 2025 Risk: low
On January 21, 2025, BioLineRx Ltd. filed a Form 6-K to report the issuance of a press release. The filing itself does not contain the details of the press rele
BioLineRx Ltd. Files 6-K Report — 6-K · Jan 17, 2025 Risk: low
On January 17, 2025, BioLineRx Ltd. filed a Form 6-K to report the issuance of a press release. This filing incorporates by reference the press release as Exhib
BioLineRx raises $50M in registered direct offering — 6-K · Jan 7, 2025 Risk: medium
On January 6, 2025, BioLineRx Ltd. entered into a securities purchase agreement with certain institutional investors for a registered direct offering. The compa
BioLineRx Ltd. Files 6-K for ADS Sale — 6-K · Jan 6, 2025 Risk: medium
On January 6, 2025, BioLineRx Ltd. announced the sale of 5,676,396 American Depositary Shares (ADSs), each representing fifteen ordinary shares. The company is
BioLineRx Ltd. Reports Q3 2024 Financial Results — 6-K · Nov 25, 2024 Risk: low
BioLineRx Ltd. announced its financial results for the three and nine months ended September 30, 2024, on November 25, 2024. The company also published its unau
BioLineRx Licenses Technology to Ayrmid Pharma — 6-K · Nov 21, 2024 Risk: medium
On November 20, 2024, BioLineRx Ltd. entered into a license agreement with Ayrmid Pharma Ltd. This agreement grants Ayrmid Pharma an exclusive, transferable, an
BioLineRx Gets 180-Day Nasdaq Bid Price Extension — 6-K · Nov 12, 2024 Risk: medium
On November 12, 2024, BioLineRx Ltd. received a notification from Nasdaq indicating that the company has been granted an additional 180-day period to regain com
BioLineRx Ltd. Files Form 6-K — 6-K · Nov 5, 2024 Risk: low
BioLineRx Ltd. filed a Form 6-K on November 5, 2024, to report the issuance of a press release. The filing itself does not contain the details of the press rele
BioLineRx Ltd. Files 6-K Reporting Press Release — 6-K · Oct 16, 2024 Risk: low
BioLineRx Ltd. filed a Form 6-K on October 16, 2024, to report the issuance of a press release. The press release, filed as Exhibit 1, is incorporated by refere
BioLineRx Ltd. Reports Annual Shareholder Meeting Results — 6-K · Oct 1, 2024 Risk: low
BioLineRx Ltd. announced the results of its Annual General Meeting of Shareholders held on October 1, 2024. The meeting took place at 3:00 p.m. Israel time, and
BioLineRx Sets Shareholder Meeting for October 1 — 6-K · Aug 19, 2024 Risk: low
BioLineRx Ltd. announced on August 19, 2024, that its Annual Meeting of Shareholders will take place on October 1, 2024, at 3:00 p.m. Israel time. The meeting w
BioLineRx Ltd. Reports Q2 2024 Financial Results — 6-K · Aug 15, 2024 Risk: medium
BioLineRx Ltd. announced its financial results for the three and six months ended June 30, 2024, on August 15, 2024. The company, headquartered at 2 HaMa'ayan S
BioLineRx Faces Breach of Contract Lawsuit — 6-K · Jun 18, 2024 Risk: medium
On June 16, 2024, Biokine Therapeutics Ltd. filed a complaint against BioLineRx Ltd. in the District Court of Jerusalem, alleging breach of contract and a purpo
BioLineRx Acquires CrystaVix JAK1/2 Inhibitor Program — 6-K · May 30, 2024 Risk: medium
BioLineRx Ltd. announced on May 30, 2024, that it has entered into a definitive agreement to acquire BioCryst Pharmaceuticals' CrystaVix program, a novel oral J
BioLineRx Ltd. Reports Q1 2024 Financial Results — 6-K · May 28, 2024 Risk: low
BioLineRx Ltd. announced its financial results for the three months ended March 31, 2024, on May 28, 2024. The company also published its unaudited interim cons
BioLineRx Ltd. Files Form 6-K Announcing Press Release — 6-K · May 24, 2024 Risk: low
On May 24, 2024, BioLineRx Ltd. issued a press release filed as Exhibit 1 to this Form 6-K. The filing itself does not contain substantive details beyond the an
BioLineRx Ltd. Files 6-K Report — 6-K · May 17, 2024 Risk: low
BioLineRx Ltd. filed a Form 6-K on May 17, 2024, to report a press release issued on the same date. The filing incorporates this press release into its effectiv
BioLineRx Ltd. Files 6-K, Announces Press Release — 6-K · May 6, 2024 Risk: low
On May 6, 2024, BioLineRx Ltd. (NASDAQ: BLRX) filed a Form 6-K to report the issuance of a press release. The press release, filed as Exhibit 1, details informa
BioLineRx Ltd. Files Form 6-K Reporting Press Release — 6-K · Apr 17, 2024 Risk: low
BioLineRx Ltd. filed a Form 6-K on April 17, 2024, to report the issuance of a press release. The filing itself does not contain the details of the press releas
BioLineRx Ltd. Files March 2024 Report on Form 6-K — 6-K · Apr 10, 2024 Risk: low
BioLineRx Ltd. announced on April 10, 2024, the issuance of a press release filed as Exhibit 1 to this Form 6-K. The press release is for the month of March 202
BioLineRx Ltd. Announces Registered Direct Offering — 6-K · Apr 1, 2024 Risk: medium
On March 28, 2024, BioLineRx Ltd. entered into a definitive agreement for a registered direct offering with certain institutional investors. The filing does not
BioLineRx Ltd. Files 20-F/A Amendment — 20-F/A · Mar 26, 2024 Risk: medium
BioLineRx Ltd. (BLRX) filed a Amended Foreign Annual Report (20-F/A) with the SEC on March 26, 2024. BioLineRx Ltd. filed an amendment to its 20-F filing on Mar
BioLineRx Ltd. Files 6-K, Incorporates Press Release — 6-K · Mar 4, 2024 Risk: low
BioLineRx Ltd. filed a Form 6-K on March 4, 2024, to report the issuance of a press release. The press release, filed as Exhibit 1, is incorporated by reference
BioLineRx Files 6-K, Incorporates Press Release into Registrations — 6-K · Feb 28, 2024 Risk: low
BioLineRx Ltd. filed a 6-K report on February 28, 2024, indicating the issuance of a press release on the same date. This press release, filed as Exhibit 1, has
BioLineRx Files 6-K, Issues Press Release on Feb 16 — 6-K · Feb 16, 2024 Risk: low
BioLineRx Ltd. filed a Form 6-K on February 16, 2024, indicating it issued a press release on the same date. This filing, under Commission file number 001-35223

Risk Profile

Risk Assessment: Of BLRX's 32 recent filings, 0 were flagged as high-risk, 12 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Top Tags

press-release (12) · filing (8) · financial-results (5) · regulatory-filing (4) · shareholder-meeting (4) · corporate-governance (4) · foreign-private-issuer (3) · sec-filing (3) · quarterly-report (3) · capital-raise (3)

Key Numbers

Quarterly Financial Results: Q2 2025 — The filing reports financial results for the second quarter of 2025.
Fiscal Year End: 2024-12-31 — The period covered by the 20-F filing.
Filing Date: 2025-03-31 — The date the 20-F was submitted to the SEC.
Gross Proceeds: $50 million — Funds raised from the registered direct offering.
ADSs Sold: 50,000,000 — Number of American Depositary Shares issued in the offering.
Price Per ADS: $1.00 — The price at which each ADS was sold.
Extension Period: 180-day — The additional time granted by Nasdaq for BioLineRx to comply with listing rules.
Expected Closing: Q3 2024 — Anticipated timeframe for the acquisition to be finalized.
SIC Code: 2834 — Pharmaceutical Preparations
License Agreement End Date: 2023-10-12 — Specific license agreement period
Purchase Agreement End Date: 2023-08-27 — Specific purchase agreement period

Related Companies

BCRX

Frequently Asked Questions

What are the latest SEC filings for Biolinerx LTD. (BLRX)?

Biolinerx LTD. has 35 recent SEC filings from Feb 2024 to Mar 2026, including 33 6-K, 1 20-F, 1 20-F/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BLRX filings?

Across 35 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 33 neutral. The dominant sentiment is neutral.

Where can I find Biolinerx LTD. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Biolinerx LTD. (BLRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Biolinerx LTD.?

Financial highlights for Biolinerx LTD. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for BLRX?

The investment thesis for BLRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Biolinerx LTD.?

Executive information for Biolinerx LTD. is extracted from SEC filings as they are enriched with AI analysis.

What are the main risk factors for Biolinerx LTD. stock?

Of BLRX's 32 assessed filings, 0 were flagged high-risk, 12 medium-risk, and 20 low-risk.

What are recent predictions and forward guidance from Biolinerx LTD.?

Forward guidance and predictions for Biolinerx LTD. are extracted from SEC filings as they are enriched.